EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Biologics vs Endoscopic Sinus Surgery in Primary Severe Uncontrolled CRSwNP: Distinct Mechanisms, Complementary Roles

Martin Desrosiers, Isam Alobid, Vibecke Backer, David Kennedy, Stella E Lee, Amber U Luong

The Journal of Allergy and Clinical Immunology: In Practice · 2026-11 · 14 (11) · 2466-2471

DOI: 10.1016/j.jaip.2026.07.045 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-11. Verfasst von Martin Desrosiers und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université de Montréal / Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada. Electronic address: desrosiers_martin@hotma…. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Endoscopy, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endoscopic sinus surgery (ESS) and biologic therapies are both effective treatments for chronic rhinosinusitis with nasal polyps (CRSwNP), yet they differ fundamentally in mechanism. Understanding these therapies as mechanistically distinct rather than interchangeable is essential for optimal patient selection and long-term disease control. ESS acts as a local, tissue-level intervention that removes inflammatory burden and enables epithelial recovery, whereas biologics provide systemic suppression of type 2 inflammation. Both ESS and biologic therapy are safe and well tolerated and represent good treatment options for CRSwNP. Despite effectiveness of both therapies in managing CRSwNP, current evidence supports ESS as a cost-effective first-line intervention following failure of intranasal topical corticosteroid therapy, with biologics reserved for refractory disease or selected high-risk phenotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinosinusitisNasal PolypsEndoscopyBiological ProductsParanasal SinusesSinusitisHumansChronic Disease

Stichwörter der Autor:innen

BiologicsCRSwNPDepemokimabDupilumabEndoscopic sinus surgeryEpitheliumMepolizumabOmalizumabTezepelumabType 2 inflammation

Substanzen

Biological Products

Autor:innen und Institutionen

  • Université de Montréal / Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada. Electronic address: desrosiers_martin@hotmail.com.
  • Hospital Clínic de Barcelona, CIBERES, IDIBAPS, Universitat Barcelona, Barcelona, Spain.
  • Department of Otorhinolaryngology-Head & Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark.
  • Sidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, Pa.
  • Department of Otolaryngology-Head & Neck Surgery, Mass General Brigham, Harvard Medical School, Boston, Mass.
  • McGovern Medical School at the University of Texas Health Science Center at Houston, Tex.

Zitieren

APA

Desrosiers, M., Alobid, I., Backer, V., Kennedy, D., Lee, S. E., & Luong, A. U. (2026). Biologics vs Endoscopic Sinus Surgery in Primary Severe Uncontrolled CRSwNP: Distinct Mechanisms, Complementary Roles. The Journal of Allergy and Clinical Immunology: In Practice, 14(11), 2466-2471. https://doi.org/10.1016/j.jaip.2026.07.045

Vancouver

Desrosiers M, Alobid I, Backer V, Kennedy D, Lee SE, Luong AU. Biologics vs Endoscopic Sinus Surgery in Primary Severe Uncontrolled CRSwNP: Distinct Mechanisms, Complementary Roles. The Journal of Allergy and Clinical Immunology: In Practice. 2026;14(11):2466-2471. doi:10.1016/j.jaip.2026.07.045

BibTeX
@article{Desrosiers2026,
  author = {Desrosiers, Martin and Alobid, Isam and Backer, Vibecke and Kennedy, David and Lee, Stella E and Luong, Amber U},
  title = {Biologics vs Endoscopic Sinus Surgery in Primary Severe Uncontrolled CRSwNP: Distinct Mechanisms, Complementary Roles},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2026},
  volume = {14},
  number = {11},
  pages = {2466--2471},
  doi = {10.1016/j.jaip.2026.07.045}
}
Kostenlos starten →